Survival analysis results indicated that CNVs in certain Ras GTPase-activating proteins significantly affect the survival periods of patients in different cancers, particularly in endometrial carcinoma, interstitial nephritis of renal papillary necrosis, and low-grade glioma. Here, RASA2 is linked to central nervous system cancer.